Latest Breaking News On - ஆலோசனை சிகிச்சை - Page 1 : comparemela.com

Monday, February 8, 2021 Physicians, physician assistants, and advance practice nurses who have sought to treat opioid-addicted patients with Schedule III-V Controlled Substances that have been approved by the United States Food and Drug Administration for that indication have had to apply for a waiver under the Drug Addiction Treatment Act of 2000. Eligible medications are presently limited to buprenorphine-containing products such as Suboxone and Subutex. [i] The waiver is oftentimes referred to as the “X-Waiver,” and permits the practitioner to provide medication-assisted treatment (MAT) to patients suffering from opioid use disorder (OUD). The Substance Abuse and Mental Health Services Administration (SAMHSA), a division of United States Department of Health and Human Services (HHS), defines MAT as “the use of medications, in combination with counseling and behavioral therapies, to provide a ‘whole-patient’ approach to the treatment of substance use disorde

United statesWhite houseDistrict of columbiaLisa murkowskir alaskaMaggie hassanCenters for diseaseUnited states department of healthHuman servicesMental health services administrationDrug administrationChildren healthUnited states foodDrug addiction treatment actSubstance abuseUnited states departmentFederal register